|
MYELODYSPLASTIC SYNDROME
|
0.100 |
Biomarker
|
group |
BEFREE |
All four cases demonstrated certain degrees of myelodysplasia and complex cytogenetic abnormalities with - 7/7q- and/or - 5/5q- or with 11q23 (KMT2A) rearrangement.
|
31371806 |
2019 |
|
MYELODYSPLASTIC SYNDROME
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we investigate the significance of additional SNP-A abnormalities in the setting of MDS and demonstrate differences in survival of patients with additional abnormalities, even those initially characterized as relatively lower risk either by cytogenetic score or IPSS-R. Our findings identify specific abnormalities, particularly KMT2A partial tandem duplication, that are invisible to conventional karyotype and potentially contribute to the poor prognosis of MDS patients.
|
31334569 |
2019 |
|
MYELODYSPLASTIC SYNDROME
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Transforming activities of the NUP98-KMT2A fusion gene associated with myelodysplasia and acute myeloid leukemia.
|
31558671 |
2019 |
|
MYELODYSPLASTIC SYNDROME
|
0.100 |
Biomarker
|
group |
BEFREE |
In this study, we assessed the role of p53 in MDS and AML cells treated with decitabine using mouse models for MLL-AF9-driven AML and mutant ASXL1-driven MDS/AML.
|
31160638 |
2019 |
|
MYELODYSPLASTIC SYNDROME
|
0.100 |
Biomarker
|
group |
BEFREE |
Homogeneously staining region (hsr) on chromosome 11 is highly specific for KMT2A amplification in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
|
31425921 |
2019 |
|
MYELODYSPLASTIC SYNDROME
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Novel LSD1 inhibitors, NCD25 and NCD38, inhibited growth of MLL-AF9 leukemia as well as erythroleukemia, megakaryoblastic leukemia and myelodysplastic syndromes (MDSs) overt leukemia cells in the concentration range that normal hematopoiesis was spared.
|
28210006 |
2017 |
|
MYELODYSPLASTIC SYNDROME
|
0.100 |
Biomarker
|
group |
BEFREE |
MLL gene amplification in acute myeloid leukemia and myelodysplastic syndromes is associated with characteristic clinicopathological findings and TP53 gene mutation.
|
25387813 |
2015 |
|
MYELODYSPLASTIC SYNDROME
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In this report, we present seven new patients with MDS diagnosis and the t(2;11)(p21;q23) in bone marrow cells; all of them without MLL gene rearrangement.
|
23949951 |
2014 |
|
MYELODYSPLASTIC SYNDROME
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Over the past few years, large-scale genomic studies of patients with myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML) have unveiled recurrent somatic mutations in genes involved in epigenetic regulation (DNMT3A, IDH1/2, TET2, ASXL1, EZH2 and MLL) and the spliceosomal machinery (SF3B1, U2AF1, SRSF2, ZRSR2, SF3A1, PRPF40B, U2AF2, and SF1).
|
23645565 |
2013 |
|
MYELODYSPLASTIC SYNDROME
|
0.100 |
Biomarker
|
group |
BEFREE |
Fluorescence in situ hybridization (FISH) showed MLL deletion in 6/10 cases, but no cryptic MLL translocations in all 15 MDS cases tested.
|
20691474 |
2011 |
|
MYELODYSPLASTIC SYNDROME
|
0.100 |
GeneticVariation
|
group |
BEFREE |
A complex MLL rearrangement identified five years after initial MDS diagnosis results in out-of-frame fusions without progression to acute leukemia.
|
22137486 |
2011 |
|
MYELODYSPLASTIC SYNDROME
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Genomic DNA PCR showed MLL partial tandem duplication in 5 of 10 MDS and 7 of 11 AML patients.
|
20072149 |
2010 |
|
MYELODYSPLASTIC SYNDROME
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Translocations and other rearrangements of the MLL gene at chromosome band 11q23 are biologically and clinically important molecular abnormalities in infant acute leukemias, leukemias associated with chemotherapeutic topoisomerase II poisons and, less often, acute leukemias in adults or myelodysplastic syndrome.
|
19277575 |
2009 |
|
MYELODYSPLASTIC SYNDROME
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Prospective tracing of MLL-FRYL clone with low MEIS1 expression from emergence during neuroblastoma treatment to diagnosis of myelodysplastic syndrome.
|
18195096 |
2008 |
|
MYELODYSPLASTIC SYNDROME
|
0.100 |
GeneticVariation
|
group |
LHGDN |
A novel MLL-SEPT2 fusion variant in therapy-related myelodysplastic syndrome.
|
18656699 |
2008 |
|
MYELODYSPLASTIC SYNDROME
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We have identified a novel fusion partner of MLL, namely the mastermind like 2 (MAML2 gene), in secondary acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) with inv(11)(q21q23).
|
17551948 |
2007 |
|
MYELODYSPLASTIC SYNDROME
|
0.100 |
Biomarker
|
group |
BEFREE |
We compared the frequency of FLT3-length mutations (FLT3-LM), FLT3-TKD, MLL-partial tandem duplications (MLL-PTD), NRAS, and KITD816 in 381 patients with MDS refractory anemia with excess blasts [RAEB] n=49; with ringed sideroblasts [RARS] n=310; chronic monomyelocytic leukemia [CMML] n=22) and in 4130 patients with AML (de novo: n=3139; secondary AML [s-AML] following MDS: n=397; therapy-related [t-AML]: n=233; relapsed: n=361).
|
17550846 |
2007 |
|
MYELODYSPLASTIC SYNDROME
|
0.100 |
Biomarker
|
group |
BEFREE |
MLL-SEPT9 fusion appears to be rare, having been described to date in only seven cases of AML and not, to our knowledge, in MDS.
|
17250889 |
2007 |
|
MYELODYSPLASTIC SYNDROME
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Twenty-one cases, including ours, of myelodysplastic syndromes and acute myelogenous leukemia with MLL amplification present in hsr or dmin were found in the literature.
|
16425025 |
2006 |
|
MYELODYSPLASTIC SYNDROME
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Rearrangements of MLL gene within exons 5-9 were not identified in this series of adult de novo MDS, indicating that this molecular abnormality is not involved in the pathogenesis of this group of hemopoietic disorders.
|
15064866 |
2004 |
|
MYELODYSPLASTIC SYNDROME
|
0.100 |
Biomarker
|
group |
BEFREE |
Fluorescence in situ hybridization analysis showed amplification of genes previously identified in myeloid and/or hematological processes, such as HER2neu, MLL, and AML1, which could represent frequent events in MDS with CK.
|
15325092 |
2004 |
|
MYELODYSPLASTIC SYNDROME
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, considering another reported case, the MLL gene seems to be not involved in the pathogenesis of MDS/AML with t(2;11) and del(5q).
|
12393282 |
2002 |
|
MYELODYSPLASTIC SYNDROME
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We detected duplication or amplification of chromosome band 11q23 with 3-7 copies of the MLL gene by fluorescence in situ hybridization in 12 out of 70 unselected patients with therapy-related myelodysplasia or acute myeloid leukemia (17%).
|
11284033 |
2001 |
|
MYELODYSPLASTIC SYNDROME
|
0.100 |
GeneticVariation
|
group |
BEFREE |
At the time of conversion to MDS, the patient had 46 chromosomes, with an 11q23/MLL translocation involving a new partner breakpoint at 2p23 and a 21q22/CBFA2 translocation involving a new partner breakpoint at 6p22.
|
10825008 |
2000 |
|
MYELODYSPLASTIC SYNDROME
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We report amplification of the MLL gene region (11q23-->11qter) in a 72-year-old woman with myelodysplastic syndrome progressing to acute myelomonocytic leukemia and in a 51-year-old man with a history of hairy cell leukemia and secondary myelodysplasia progressing to acute myelogenous leukemia.
|
11063808 |
2000 |